EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.

ABSTRACT:

Background

A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to maximize the clinical benefits. Eph receptors have been shown to play essential roles in tumor immunity. However, the association between EPH gene mutation and ICI response is lacking.

Methods

Clinical data and whole-exome sequencing (WES) data from published studies were collected and consolidated as a discovery cohort to analyze the association between EPH gene mutation and efficacy of ICI therapy. Another independent cohort from Memorial Sloan Kettering Cancer Center (MSKCC) was adopted to validate our findings. The Cancer Genome Atlas (TCGA) cohort was used to perform a

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC7852135 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature